Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the clinical outcomes of the Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) after 1 day, 1 week,1 month, 3 months, 6 months and one year of follow-up, with the intent to evaluate the efficacy of using MP-TSCPC to treat glaucoma patients.

Detailed Description
-----------------
Patients will be submitted to MP-TSCPC throughout the year of 2020, according to parameters determined by the Principal Investigator and executed by the Principal Investigator, after signing the Consent Form and agreeing on having their data used for research purpose. Postsurgical follow up visits will be scheduled for 1 month, 3 months, 6 months and 12 months. Patients IOP, number of medications, visual acuity, visual field, iris color, retinal nerve fiber layer thickness on OCT and any complications (iritis, corneal edema, hyphema, vitreous hemorrhage, vision loss, cataract progression or hypotony maculopathy) will be measured by trained ophthalmic assistants supervised by the Principal Investigator and documented at each visit. Authorized Mayo Clinic personnel will perform chart reviews; using administrative data as designated by Dr. Dorairaj. The data will be statistically analyzed to illustrate the results and determine if the objectives and primary and secondary endpoints were achieved

Official Title
-----------------
Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients: Clinical Outcomes. Prospective Observational Cohort Study

Conditions
-----------------
Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnose of glaucoma Indication to be submitted to the procedure Exclusion Criteria: Significant thinning of the sclera Current eye infection or inflammation Intraocular surgery performed less than 2 months prior to the enrollment in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change In IOP | Change in intraocular pressure (IOP), reported in millimeters of mercury (mm Hg) | Baseline, 12 months post procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of anti-glaucoma medications | Number of anti-glaucoma medication drops | 12 months | 
| Change in visual acuity | Change in visual acuity score | Baseline, 12 months post procedure | 
| Change in cup-disc ratio | Ratio of the size of the optic cup to the optic disc | Baseline, 12 months post procedure | 
| Change in visual field | Total area visible in peripheral vision when focused on a central point, reported in degrees | Baseline, 12 months post procedure | 
| Change in iris color | Number of subjects to have a change in their iris color | Baseline, 12 months post procedure | 
| Complications | Number of subjects to experience complications from the procedure | 12 months |